


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compound characterized in that it corresponds to formula (1)



in which

- each group R^1 is identical to the other group R^1 and represents:
 - a C_1 to C_6 alkyl, C_2 to C_6 alkenyl or C_2 to C_6 alkynyl group,
 - a $(CH_2)_n$ benzyl group in which n is equal to 0 or 1,
 - a $(CH_2)_m(C_3$ to C_6 cycloalkyl) group in which m is equal to 0 or 1,
- each of the alkyl, alkenyl, alkynyl, benzyl or cycloalkyl groups being substituted with one or two group(s) represented by the group A;
- the group A represents:

- a carboxylate group COOH or COOR, R representing a C₁ to C₆ alkyl or CH₂phenyl group;
- a sulfonate group SO₃H or SO₃R', R' representing a C₁ to C₆ alkyl or CH₂phenyl group;
- a phosphonate group PO₃H₂ or PO₃R₂"R'"', R" and R'" independently representing H, or a C₁ to C₆ alkyl or CH₂phenyl group;
- each group R² is identical to the other group R² and represents a C₁ to C₆ alkyl, C₂ to C₆ alkenyl or C₂ to C₆ alkynyl group, each alkyl, alkenyl or alkynyl group being free or substituted with the group B;
- the group B represents:
 - a carboxylate group, COOH or COOR', R' representing a C₁ to C₆ alkyl or CH₂phenyl group;
 - a phenyl group that is free or substituted with one or more radicals chosen from a halogen atom, an optionally protected hydroxyl radical, a C₁ to C₄ alkyl group, a cyano group, a free, salified or esterified carboxyl group or an amide group;
- each group R³ is identical to the other group R³ and represents a hydrogen atom.

2. (Original) Compound according to Claim 1, characterized in that R¹ is chosen from C₁ to C₆ alkyl, C₂ to C₆ alkenyl and benzyl groups, each of these groups being

substituted with one or two group(s) represented by the group A as defined in Claim 1.

3. (Original) Compound according to either of Claims 1 and 2, characterized in that R² is chosen from a C₁ to C₆ alkyl group and a C₂ to C₆ alkenyl group, it being possible for each of these groups to be substituted with one or two group(s) represented by the group B as defined in Claim 1.

4. (Original) Compound according to any one of Claims 1 to 3, characterized in that R¹ represents an ethyl group substituted with a sulfonic group, a phosphonic group or a carboxylic group, that is free, salified or esterified, and R² represents an ethyl group substituted with a free or substituted phenyl group.

5. (Original). Compound according to any one of Claims 1 to 4, characterized in that it is 4,4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.

6. (Original) Compound according to Claim 5, characterized in that it is 4(S),4'(S),3(S),3'(S)-4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.

7. (Original) Compound according to any one of Claims 1 to 6, characterized in that it is for use in therapeutics.

8. (Original) Pharmaceutical composition, characterized in that it comprises a compound according to any one of Claims 1 to 6.

9. (Currently Amended) ~~Use of a compound according to any one of Claims 1 to 6, as a selective inhibitor with regard to a method of selectively inhibiting aminopeptidase A, which comprises administering to a patient in need thereof an efficient amount of a compound of formula (1) according to claim 1.~~

10. (Currently Amended) ~~Use of a compound according to any one of Claims 1 to 6, for preparing a medicinal product for use in the treatment of a method for treating arterial hypertension and of directly and indirectly related diseases, which comprises administering to a patient in need thereof an efficient amount of a compound of formula (1) according to claim 1.~~

11. (Currently Amended) ~~Use of a compound according to any one of Claims 1 to 6, for preparing a medicinal product for use in the treatment of a method for treating a disease chosen from selected from the group consisting of primary or secondary arterial hypertension, an ictus, myocardial ischemia, cardiac insufficiency and renal insufficiency, myocardial infarction, a peripheral vascular disease, diabetic~~

proteinuria proteinuria, syndrome X, glaucoma,
neurodegenerative diseases and memory disorders, which
comprises administering to a patient in need thereof an
efficient amount of a compound of formula (1) according to
claim 1.

12. (Currently Amended) Use of a compound according
to any one of Claims 1 to 6, for preparing a medicinal product
for use in the treatment ofA method for treating ischemic and
tumoral pathologies in which aminopeptidase A is involved,
which comprises administering to a patient in need thereof an
efficient amount of a compound of formula (1) according to
claim 1.

13. (New) A method according to claim 9, wherein the compound of formula (1) is 4,4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.

14. (New) A method according to claim 9, wherein the compound of formula (1) is 4(S),4'(S),3(S),3'(S)-4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.

15. (New) A method according to claim 10, wherein the compound of formula (1) is 4,4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.

16. (New) A method according to claim 10, wherein the compound of formula (1) is 4(S),4'(S),3(S),3'(S)-4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.

17. (New) A method according to claim 11, wherein the compound of formula (1) is 4,4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.

18. (New) A method according to claim 11, wherein the compound of formula (1) is 4(S),4'(S),3(S),3'(S)-4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.

19. (New) A method according to claim 12, wherein the compound of formula (1) is 4,4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.

20. (New) A method according to claim 12, wherein the compound of formula (1) is 4(S),4'(S),3(S),3'(S)-4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid.